Goldman Sachs
AVDL

Goldman Sachs’s Avadel Pharmaceuticals AVDL Stock Holding History

Goldman Sachs’s Portfolio AVDL Stock Details AVDL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-655,058
Closed -$14.1M – 6463
2025
Q4 		$14.1M Buy
655,058
+131,986
+25% +$2.56M ﹤0.01% 2723
2025
Q3 		$7.99M Buy
523,072
+101,788
+24% +$1.32M ﹤0.01% 3191
2025
Q2 		$3.73M Sell
421,284
-306,585
-42% -$2.69M ﹤0.01% 3687
2025
Q1 		$5.7M Sell
727,869
-1,418,316
-66% -$11.9M ﹤0.01% 3228
2024
Q4 		$22.6M Buy
2,146,185
+286,217
+15% +$3.48M ﹤0.01% 2012
2024
Q3 		$24.4M Buy
+1,859,968
New +$28.3M ﹤0.01% 1886
2024
Q2 		– Sell
-374,203
Closed -$6.32M – 5648
2024
Q1 		$6.32M Sell
374,203
-113,048
-23% -$1.68M ﹤0.01% 2883
2023
Q4 		$6.88M Buy
487,251
+125,799
+35% +$1.48M ﹤0.01% 2871
2023
Q3 		$3.72M Buy
361,452
+148,653
+70% +$1.99M ﹤0.01% 3254
2023
Q2 		$3.51M Buy
212,799
+160,431
+306% +$2.09M ﹤0.01% 3416
2023
Q1 		$480K Buy
52,368
+24,050
+85% +$198K ﹤0.01% 4840
2022
Q4 		$203K Sell
28,318
-3,126
-10% -$21.9K ﹤0.01% 5301
2022
Q3 		$158K Buy
31,444
+10,646
+51% +$58.6K ﹤0.01% 5556
2022
Q2 		$51K Sell
20,798
-24,148
-54% -$99.1K ﹤0.01% 6021
2022
Q1 		$307K Sell
44,946
-12,057
-21% -$82.9K ﹤0.01% 5650
2021
Q4 		$461K Buy
57,003
+16,654
+41% +$152K ﹤0.01% 5439
2021
Q3 		$395K Buy
40,349
+5,834
+17% +$45.9K ﹤0.01% 5340
2021
Q2 		$232K Buy
34,515
+14,661
+74% +$116K ﹤0.01% 5673
2021
Q1 		$179K Sell
19,854
-55,521
-74% -$449K ﹤0.01% 5681
2020
Q4 		$504K Buy
75,375
+50,416
+202% +$315K ﹤0.01% 4599
2020
Q3 		$126K Buy
+24,959
New +$182K ﹤0.01% 5038
2020
Q2 		– Sell
-191,440
Closed -$1.52M – 5192
2020
Q1 		$1.52M Buy
+191,440
New +$1.47M ﹤0.01% 3483
2019
Q1 		– Sell
-16,000
Closed -$41K – 5109
2018
Q4 		$41K Sell
16,000
-4,877
-23% -$16.6K ﹤0.01% 5110
2018
Q3 		$92K Sell
20,877
-16,570
-44% -$89.5K ﹤0.01% 5160
2018
Q2 		$230K Buy
37,447
+10,937
+41% +$76.7K ﹤0.01% 4928
2018
Q1 		$193K Buy
26,510
+212
+0.8% +$1.86K ﹤0.01% 5022
2017
Q4 		$216K Sell
26,298
-8,861
-25% -$83.1K ﹤0.01% 5390
2017
Q3 		$369K Buy
35,159
+1,888
+6% +$18K ﹤0.01% 5317
2017
Q2 		$367K Sell
33,271
-43,667
-57% -$438K ﹤0.01% 5336
2017
Q1 		$745K Sell
76,938
-3,996
-5% -$40K ﹤0.01% 4654
2016
Q4 		$841K Buy
80,934
+49,308
+156% +$542K ﹤0.01% 4601
2016
Q3 		$392K Buy
31,626
+9,630
+44% +$126K ﹤0.01% 5262
2016
Q2 		$236K Buy
21,996
+6,996
+47% +$74.6K ﹤0.01% 5558
2016
Q1 		$166K Buy
+15,000
New +$149K ﹤0.01% 5761

Other funds holding AVDL

IA
IFP Advisors Tampa, Florida $5.54B AUM 27.43% 1-Year Est. Return
HNB
Huntington National Bank Columbus, Ohio $20.6B AUM 34.61% 1-Year Est. Return

Goldman Sachs's AVDL Position: Q1 2026 in Review

Goldman Sachs sold out of Avadel Pharmaceuticals (AVDL) in Q1 2026, closing a stake of 655,058 shares — an estimated $14.1M sold.

Goldman Sachs first reported a position in AVDL in Q1 2016 and held it in 34 quarters. The position peaked at $24.4M in Q3 2024. 2 funds tracked by Wall St. Rank hold AVDL as of Q1 2026.

  • Goldman Sachs reported no remaining Avadel Pharmaceuticals position as of Q1 2026 after selling out during the quarter.
  • Goldman Sachs sold 655,058 Avadel Pharmaceuticals shares in Q1 2026, an estimated $14.1M.
  • Goldman Sachs first reported a position in Avadel Pharmaceuticals in Q1 2016 and held it in 34 quarters.
  • Goldman Sachs's Avadel Pharmaceuticals position peaked at $24.4M in Q3 2024.
  • 2 funds tracked by Wall St. Rank held Avadel Pharmaceuticals as of Q1 2026.

Based on Goldman Sachs's 13F filing for Q1 2026, filed 15 May 2026.